Arbutus Biopharma Corporation (ABUS) Dividend History

Company News

• Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.

  Moderna's stock has been struggling since the end of the COVID-19 pandemic, with a Wall Street analyst cutting her price target and reiterating a sell recommendation. The analyst cited issues such as cost-management struggles and legal headaches, as well as a hold on a late-stage trial for a norovirus vaccine candidate.

  The Motley Fool

  Featured Companies: MRNA ROIV
• Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?

  Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  Zacks Investment Research

  Featured Companies: RARE
• Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels

  Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress

  GlobeNewswire Inc.
• Moderna Shares Under Pressure as Flu Vaccine Fails to Meet All Endpoints

  Investing.com

  Featured Companies: MRNA PFE
• The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study

  Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The FDA has approved AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu (trastuzumab deruxtecan) for adult patients with unresectable or metastatic HER2-positive breast cancer. The approval covers patients who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of therapy. AstraZeneca's Dapagliflozin Meets Primary Goal In Heart Failure Patients AstraZeneca announced high-level results from the DELIVER Phase 3 trial of Farxiga (dapagliflozin) to treat heart failure patients. Data showed Farxiga reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular death or worsening heart failure. AstraZeneca's Ultomiris Aces Late-Stage Trial In Rare Autoimmune Disease AstraZeneca announced topline data from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab-cwvz) in neuromyelitis optica spectrum disorder. Data exhibited that Ultomiris achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD compared to the ...

  Benzinga

  Featured Companies: AGIO ALDX AXGN BCRX CHRS IBB INCY INMB JAZZ KPTI NTLA PRTA RARE SGMO TBPH VNDA XNCR